FIELD: medicine.
SUBSTANCE: invention relates to application of compound of formula I or II given below in preparation of medication for elimination or attenuation of microorganisms' growth in the way which includes subjection of said compound to exposure to source of light of photodynamic therapy or source of ultrasound of ultrasonic (sonodynamic) therapy, where X1, X2, X3 and X4 independently represent hydrogen atom, lipophylic part of molecule, phenyl group, lower alkyl, alkaryl or aralkyl group or cationic group of the following formula: -L-R1-N+(R2)(R3)R4 where: L represents binding (linking) part of molecule or is absent; R1 represents lower alkylene, lower alkenylene or lower alkinylene, which is optionally substituted with one or several substituents selected from lower alkyl, lower alkylene (optionally interrupted with oxygen), fluorine, OR5, C(O)R6, C(O)OR7, C(O)NR8R9, NR10R11 and N+R12R13R14; and R2, R3 and R4 independently represent H, aryl, lower alkyl, lower alkenyl or lower alkinyl, three latter of which are optionally substituted with one or several substituents selected from lower alkyl, lower alkylene (optionally interrupted with oxygen), aryl, OR5, C(O)R6, C(O)OR7, C(O)NR8R9, NR10R11 and N+R12R13R14; Z represents -CH or N; Y1, Y2, Y3 and Y4 are absent or independently represent aryl, lower alkyl, lower alkenyl or lower alkinyl, three latter of which are optionally substituted with one or several substituents selected from lower alkyl, lower alkylene (optionally interrupted with oxygen), aryl, OR5, C(O)R6, C(O)OR7, C(O)NR8R9, NR10R11 and N+R12R13R14, or, taken together with pyrrolic ring, to which they are bound, can form cyclic group; and R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14 independently represent H or lower alkyl; M represents element of metal or metalloid; on condition that at least one of X1, X2, X3 and X4 is cationic group, defined above, and at least one of X1, X2, X3 and X4 represents hydrogen atom, phenyl group, lipophylic part of molecule or lower alkyl, alkaryl or aralkyl group, said microorganisms being selected from bacteria, mycoplasms, yeasts and/or fungi. Invention also relates to method of treating patient who needs treatment with antimicrobial agent and method of eliminating microorganisms in vitro, including contact of said microorganisms with compound of formula
and
EFFECT: novel application of porphyrin compounds as antimicrobial agent, said microorganisms being selected from bacteria, mycoplasms, yeasts or fungi.
67 cl, 13 dwg, 4 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
CATALYST SYSTEM | 2003 |
|
RU2326123C2 |
ORGANIC COMPOUNDS | 2005 |
|
RU2411239C2 |
NOVEL PORPHYRIN DERIVATIVES, PARTICULARLY CHLORINS AND/OR BACTERIOCHLORINS AND USE THEREOF IN PHOTODYNAMIC THERAPY | 2005 |
|
RU2399622C2 |
METHOD FOR TREATING THE CASES OF CHRONIC POLYARTHRITIS | 1993 |
|
RU2179023C2 |
AROMATIC DIKETONE DERIVATIVES, METHODS FOR PRODUCTION THEREOF AND USES AS PHARMACEUTICALS | 2000 |
|
RU2252211C2 |
NOVEL INDOLE DERIVATIVES HAVING IκB KINASE β INHIBITING ACTIVITY | 2008 |
|
RU2470918C2 |
CONDENSED AZEPINES, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF, METHOD FOR TREATMENT BY USING INDICATED COMPOSITION | 2001 |
|
RU2259367C2 |
INHIBITORS OF DIPEPTIDYL-PEPTIDASE IV | 2001 |
|
RU2283303C2 |
DERIVATIVES OF PHENYLAMIDINE | 1996 |
|
RU2184726C2 |
BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, USEFUL IN TREATMENT OF HEPATITIS C | 2010 |
|
RU2540332C2 |
Authors
Dates
2010-03-10—Published
2005-06-22—Filed